TScan Therapeutics Inc. (TCRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.25 per share a year ago.
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago.
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.
TScan Therapeutics Inc. (TCRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has TScan Therapeutics Inc. ever had a stock split?
TScan Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gavin MacBeath CEO | NASDAQ (NMS) Exchange | 89854M101 CUSIP |
| US Country | 200 Employees | - Last Dividend | - Last Split | 16 Jul 2021 IPO Date |
Overview
TScan Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company operating primarily in the United States, committed to the development of innovative T cell receptor-engineered T cell (TCR-T) therapies aimed at treating cancer patients. At its core, TScan's mission revolves around leveraging cutting-edge science to discover and develop therapies that have the potential to significantly improve outcomes for cancer patients. Founded in 2018 and based in Waltham, Massachusetts, TScan Therapeutics is at the forefront of TCR-T therapy research and development, collaborating with leading institutions such as the Novartis Institutes for BioMedical Research, Inc., and Amgen Inc. These collaborations focus on discovering and developing novel TCR-T therapies and identifying antigens recognized by T cells in patients with specific diseases, respectively. Moreover, TScan is exploring the realm of vaccine development for infectious diseases, such as SARS-CoV-2, indicating its versatility and commitment to addressing both cancer and infectious diseases.
Products and Services
- TSC-100 and TSC-101
These are TScan's lead product candidates, currently undergoing Phase I clinical trials. They are designed for the treatment of patients with hematologic malignancies, aiming to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. This therapeutic approach represents a potential breakthrough in treating blood cancers, focusing on enhancing the body's immune response to combat malignant cells effectively.
- TSC-200 series (TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204)
Part of an ambitious development program, these candidates address the treatment of solid tumors and are all in Phase 1 clinical trials. Each product targets different mechanisms and antigens to attack solid tumors, showcasing TScan’s comprehensive approach to tackling cancer's complexity. TSC-202, in particular, emphasizes the company's focus on broadening its portfolio to target a variety of solid tumors, offering new hope for patients with these challenging conditions.
- Vaccines for Infectious Diseases
In response to the global health crisis instigated by infectious diseases like SARS-CoV-2, TScan Therapeutics has expanded its research and development efforts to include vaccines. This diversification illustrates the company’s adaptability and commitment to leveraging its expertise in immunology and T cell therapies beyond cancer treatment, aiming to offer innovative solutions for pressing public health challenges.
Contact Information
